Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
نویسندگان
چکیده
Background The majority of BRCA1-mutant breast cancers are characterized by a triple-negative phenotype and basal-like molecular subtype, associated with aggressive clinical behavior. Current treatment options limited, highlighting the need for development novel targeted therapies this tumor subtype.
منابع مشابه
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes, resulting in increased activity of the MYC pathway. In primary breast tumors, MYC signaling did ...
متن کاملmiR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells
Expression of miR-342 has been strongly correlated with estrogen receptor (ER) status in breast cancer, where it is highest in ER-positive and lowest in triple-negative tumors. We investigated the effects of miR-342 transfection in the triple-negative breast cancer cell lines MDA-MB-231 and HCC1937, the latter carrying a germ-line BRCA1 mutation. Reconstitution of miR-342 led to caspase-depende...
متن کاملTargeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal
ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types. Notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently has no effective therapy. To date, clinically applicable targeted cancer therapy based on ARID1A mutational status has not been described. Here we show that inhibition of the EZH2 methyltransferase acts in a syn...
متن کاملThe synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition
Colorectal cancer (CRC) is a leading cause of cancer-related death throughout the world. Despite improved screening efforts, most CRCs are diagnosed at late stages when surgery alone is not curative. Moreover, the low 5-year survival rate (~8-13%) for those living with stage IV CRC highlights the need for better treatment options. Many current chemotherapeutic approaches are non-specific and as...
متن کاملGenetic diagnosis of cancer: diagnosis of mutations in BRCA1 and BRCA2 in breast cancer
During the last two decays the tremendous success in molecular biology and genetics which has surprised the entire world. So that today the sequencing of whole genome has been possible for each human individual to estimate its being affected with cardiovascular and cancer diseases. However, these achievements have some important limitations and deep ethical issues which might be ignored. Geneti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Geburtshilfe Und Frauenheilkunde
سال: 2022
ISSN: ['1438-8804', '2199-6989', '0016-5751']
DOI: https://doi.org/10.1055/s-0042-1757008